Search

Showing total 310 results
310 results

Search Results

1. Issue Information.

2. Titles in research articles: Changes across time and discipline.

6. Editorial: ARFI‐based techniques are better than VCTE for diagnosing advanced fibrosis in severe obesity—Authors' reply.

7. Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply.

9. Editorial: Has MetALD met the presumption? Authors' reply.

10. Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply.

13. Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply.

14. Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply.

17. Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply.

18. Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply.

19. Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms—still a long way to go... Authors' reply'.

21. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply.

23. Letter: Severe underweight and sarcopenia in decompensated cirrhosis are associated with high FGF21 levels—authors' reply.

24. Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases. Authors' reply.

39. Letter: Exploring the clinical utility of ammonia in critically ill patients with cirrhosis: More to do? Authors' reply.

41. Letter: Rethinking the lower incidence of HCC in HIV‐infected patients—A closer look at confounding factors. Authors' reply.

44. Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States—Authors' reply.

48. Editorial: Feeling better about NASH—Authors' reply.

49. Editorial: The use of Baveno VI and VII criteria for portal hypertension and varices in patients with hepatocellular carcinoma—Authors' reply.